Dentsply Sirona price target raised to $17 from $15 at Evercore ISI

Evercore ISI raised the firm’s price target on Dentsply Sirona (XRAY) to $17 from $15 and keeps an In Line rating on the shares. The firm notes that the company’s Q1 earnings provide further data points that dental is starting to recover post its COVID hangover. While not out of the woods yet, and clearly tariffs and macro concerns are weighing on results, better ex-U.S. sentiment should also help to offset a portion of the macro pressure, Evercore argues. Dentsply still has “a lot of wood to chop” to get the dental business on the right long-term track, but the firm is encouraged by the hard work that is being done to get there. However, it remains on the sidelines until it sees signs that these operational improvements are starting to yield greater financial results.